Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Quantitation of Neurotoxic Metabolites of the Kynurenine Pathway by Laser Desorption Ionization Mass Spectrometry (LDI-MS).

Lahiri P, Dhaware D, Singh A, Panchagnula V, Ghosh D.

Methods Mol Biol. 2019;1996:113-129. doi: 10.1007/978-1-4939-9488-5_11.

PMID:
31127552
2.

Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.

Birner A, Platzer M, Bengesser SA, Dalkner N, Fellendorf FT, Queissner R, Pilz R, Rauch P, Maget A, Hamm C, Herzog-Eberhard S, Mangge H, Fuchs D, Moll N, Zelzer S, Schütze G, Schwarz M, Reininghaus B, Kapfhammer HP, Reininghaus EZ.

PLoS One. 2017 Feb 27;12(2):e0172699. doi: 10.1371/journal.pone.0172699. eCollection 2017.

3.

Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.

Schwarz MJ, Guillemin GJ, Teipel SJ, Buerger K, Hampel H.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):345-52. doi: 10.1007/s00406-012-0384-x. Epub 2012 Nov 29.

PMID:
23192697
4.

The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.

Tan L, Yu JT, Tan L.

J Neurol Sci. 2012 Dec 15;323(1-2):1-8. doi: 10.1016/j.jns.2012.08.005. Epub 2012 Aug 29. Review.

PMID:
22939820
5.

Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.

Meier TB, Drevets WC, Wurfel BE, Ford BN, Morris HM, Victor TA, Bodurka J, Teague TK, Dantzer R, Savitz J.

Brain Behav Immun. 2016 Mar;53:39-48. doi: 10.1016/j.bbi.2015.11.003. Epub 2015 Nov 4.

6.

Kynurenine and its metabolites in Alzheimer's disease patients.

Gulaj E, Pawlak K, Bien B, Pawlak D.

Adv Med Sci. 2010;55(2):204-11. doi: 10.2478/v10039-010-0023-6.

PMID:
20639188
7.

Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.

Yan EB, Frugier T, Lim CK, Heng B, Sundaram G, Tan M, Rosenfeld JV, Walker DW, Guillemin GJ, Morganti-Kossmann MC.

J Neuroinflammation. 2015 May 30;12:110. doi: 10.1186/s12974-015-0328-2.

8.

Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.

Breda C, Sathyasaikumar KV, Sograte Idrissi S, Notarangelo FM, Estranero JG, Moore GG, Green EW, Kyriacou CP, Schwarcz R, Giorgini F.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):5435-40. doi: 10.1073/pnas.1604453113. Epub 2016 Apr 25.

9.

Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.

Castellano-Gonzalez G, Jacobs KR, Don E, Cole NJ, Adams S, Lim CK, Lovejoy DB, Guillemin GJ.

Neurotox Res. 2019 Apr;35(3):530-541. doi: 10.1007/s12640-019-9997-4. Epub 2019 Jan 21.

PMID:
30666558
10.
11.

Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.

Aeinehband S, Brenner P, Ståhl S, Bhat M, Fidock MD, Khademi M, Olsson T, Engberg G, Jokinen J, Erhardt S, Piehl F.

Brain Behav Immun. 2016 Jan;51:47-55. doi: 10.1016/j.bbi.2015.07.016. Epub 2015 Jul 17.

PMID:
26189678
12.

The Metabolic Factor Kynurenic Acid of Kynurenine Pathway Predicts Major Depressive Disorder.

Liu H, Ding L, Zhang H, Mellor D, Wu H, Zhao D, Wu C, Lin Z, Yuan J, Peng D.

Front Psychiatry. 2018 Nov 19;9:552. doi: 10.3389/fpsyt.2018.00552. eCollection 2018.

13.

Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.

Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A, et al.

Brain. 1992 Oct;115 ( Pt 5):1249-73.

PMID:
1422788
14.

Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients.

Schwieler L, Samuelsson M, Frye MA, Bhat M, Schuppe-Koistinen I, Jungholm O, Johansson AG, Landén M, Sellgren CM, Erhardt S.

J Neuroinflammation. 2016 Feb 29;13(1):51. doi: 10.1186/s12974-016-0517-7.

15.

Effect of Kynurenic Acid on Pupae Viability of Drosophila melanogaster cinnabar and cardinal Eye Color Mutants with Altered Tryptophan-Kynurenine Metabolism.

Navrotskaya V, Wnorowski A, Turski W, Oxenkrug G.

Neurotox Res. 2018 Aug;34(2):324-331. doi: 10.1007/s12640-018-9891-5. Epub 2018 Apr 4.

PMID:
29619629
16.

Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.

Wang XD, Notarangelo FM, Wang JZ, Schwarcz R.

Brain Res. 2012 May 21;1455:1-9. doi: 10.1016/j.brainres.2012.03.026. Epub 2012 Mar 17.

17.

The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.

Guloksuz S, Arts B, Walter S, Drukker M, Rodriguez L, Myint AM, Schwarz MJ, Ponds R, van Os J, Kenis G, Rutten BP.

Brain Behav Immun. 2015 Aug;48:48-52. doi: 10.1016/j.bbi.2015.02.029. Epub 2015 Mar 9.

PMID:
25765557
18.

L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.

Fujigaki H, Yamamoto Y, Saito K.

Neuropharmacology. 2017 Jan;112(Pt B):264-274. doi: 10.1016/j.neuropharm.2016.01.011. Epub 2016 Jan 6. Review.

PMID:
26767951
19.

A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma.

Orsatti L, Speziale R, Orsale MV, Caretti F, Veneziano M, Zini M, Monteagudo E, Lyons K, Beconi M, Chan K, Herbst T, Toledo-Sherman L, Munoz-Sanjuan I, Bonelli F, Dominguez C.

J Pharm Biomed Anal. 2015 Mar 25;107:426-31. doi: 10.1016/j.jpba.2015.01.030. Epub 2015 Jan 24.

PMID:
25668794
20.

Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.

Notarangelo FM, Wilson EH, Horning KJ, Thomas MA, Harris TH, Fang Q, Hunter CA, Schwarcz R.

Schizophr Res. 2014 Jan;152(1):261-7. doi: 10.1016/j.schres.2013.11.011. Epub 2013 Dec 15.

Supplemental Content

Support Center